24/08/2026 Johnson & Johnson received FDA approval for nipocalimab for the treatment of warm autoimmune hemolytic anemia US FDA granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus Johnson & Johnson received FDA approval for nipocalimab for the treatment of warm autoimmune hemolytic anemia (Ref) Johnson & Johnson announced that the US FDA approved IMAAVY® (nipocalimab-aahu; FcRn blocker) for adults and paediatric patients 12 years of age and older wit